Immunotherapeutic tumor treatment method
Provided is a method of administering to a patient having cancer: (a) a 4-1BB agonist; (b) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and/or (c) a toll-like receptor agonist, as well as related compositions, kits and compositions.
1. A method of administration comprising:
administering to a subject having a cancer a 4-1BB agonist, and
administering to the subject (i) an interleukin-2 receptor beta (IL-2Rβ)-activating amount of a long acting IL-2Rβ-preferential agonist of a formula:
or a pharmaceutically acceptable salt form thereof, wherein IL-2 is an interleukin-2, and (n) ranges from 3 to 4,000, and (ii) a toll-like receptor (TLR) agonist selected from
or a pharmaceutically acceptable salt thereof, wherein each n for each of Compounds 5 and 6 is independently an integer from 40 to 350.
2. The method of claim 1 , wherein each of the 4-1BB agonist, the toll-like receptor agonist and the long acting IL-2Rβ-preferential agonist are administered at substantially the same time.
3. The method of claim 1 , wherein the 4-1BB agonist is administered separately from at least one of the toll-like receptor agonist and the long acting IL-2Rβ-preferential agonist.
4. The method of claim 1 , wherein the toll-like receptor agonist is administered separately from at least one of the 4-1BB agonist and the long acting IL-2Rβ-preferential agonist.
5. The method of claim 1 , wherein the 4-1BB agonist is administered to the subject systemically.
6. The method of claim 1 , wherein the 4-1BB agonist is administered to the subject intravenously.
7. The method of claim 1 , wherein the 4-1BB agonist and the long acting IL-2Rβ-preferential agonist are administered in the same formulation.
8. The method of claim 1 , wherein the toll-like receptor agonist is administered directly to cancer tissue in the subject.
9. The method of claim 1 , wherein the toll-like receptor agonist is administered directly to a solid cancer of the subject.
10. The method of claim 1 , wherein the toll-like receptor agonist is administered by a method selected from intratumoral injection and peritumoral injection.
11. The method of claim 1 , wherein the long acting IL-2Rβ-preferential agonist is administered to the subject systemically.
12. The method of claim 1 , wherein the long acting IL-2Rβ-preferential agonist is administered to the subject intravenously.
13. The method of claim 1 , wherein the 4-1BB agonist is an antibody that selectively binds to the 4-1BB receptor.
14. The method of claim 1 , wherein the 4-1BB agonist is an anti-CD137 antibody.
15. The method of claim 1 , wherein the 4-1BB agonist is selected from urelumab and utomilumab.
16. The method of claim 1 , wherein the long acting IL-2Rβ-preferential agonist is (2,7-(bis-methoxyPEG 10kD -carboxyamide)(9H-fluorene-9-yl)methyl N-carbamate) 4-6 interleukin-2.
17. The method of claim 1 , wherein the cancer is a solid cancer.
18. The method of claim 1 , wherein the cancer is selected from breast cancer, ovarian cancer, colon cancer, prostate cancer, bone cancer, colorectal cancer, gastric cancer, lymphoma, malignant melanoma, liver cancer, small cell lung cancer, non-small cell lung cancer, pancreatic cancer, thyroid cancers, kidney cancer, cancer of the bile duct, brain cancer, cervical cancer, maxillary sinus cancer, bladder cancer, esophageal cancer, Hodgkin's disease and adrenocortical cancer.
19. The method of claim 1 , wherein administration of the 4-1BB agonist, the IL-2Rβ-activating amount of a long acting IL-2Rβ-preferential agonist, and the toll-like receptor agonist is effective to promote activation of the immune system.
20. The method of claim 1 , wherein administration of the 4-1BB agonist the IL-2Rβ-activating amount of a long acting IL-2Rβ-preferential agonist, and the toll-like receptor agonist is effective to promote activation of at least one of CD8 T cells, CD11c+ and CD8+ dendritic cells, and neutrophils.
21. The method of claim 1 , wherein administration of the 4-1BB agonist, the IL-2Rβ-activating amount of a long acting IL-2Rβ-preferential agonist, and the toll-like receptor agonist is effective to suppress T regulatory cells, macrophages, and monocytes.
22. The method of claim 1 , wherein administration of the 4-1BB agonist, the IL-2Rβ-activating amount of a long acting IL-2Rβ-preferential agonist, and the toll-like receptor agonist is effective to produce an abscopal effect on the cancer.